Aly-Khan Lalani

Thank you @JuravinskiRI for this award to launch ELEVATe-PM! We aim to integrate innovative MRD blood tests in the curative setting - starting with RCC, bladder cancer, & AML - while harnessing AI/data analytics to enhance efficiencies @HamHealthSci @McMasterU @StJoesHamilton

Go #BehindTheScenes with Dr. @LalaniMD and Dr. @WallisCJD as they film live from Las Vegas at @AmerUrological’s #AUA25! In Episode 22, dropping tomorrow, they dive into exciting #BladderCancer research and clinical trial results. theviewongu.ca

One of the reasons I love @kidneycan's #KCRS25: Hearing luminaries in the field of #kidneycancer present their take on data hot off the press. So cool to see @DrChoueiri @motzermd @NaomiHaas5 #McDermott sharing a stage & offering perspective on the latest from @ASCO, @myESMO &…

#KCRS25 Excellent opening session on non clear cell RCC: arguments/fallacies, rational patient selection, trial designs, regulatory guidance — coalescing around a collaborative framework, ⬇️ barriers, ⬆️ equity @DrChoueiri @HHammersMD @DrRanaMcKay @arihakimi @kidneycan

Huge Congratulations 🎉 to Dr. @lalaniMD (former @DanaFarber_GU post-doc) who keeps pushing the boundaries and excelling, now @JuravinskiRI in Canada 🇨🇦!

Episode 26 is now live! Join Dr. @WinsonCheung as he unpacks the evolving role of #RealWorldEvidence in #Oncology with Dr. @LalaniMD and Dr. @WallisCJD. From data pitfalls to practice-changing potential, this is one conversation you don’t want to miss. theviewongu.com

In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity. The likelihood of a response was higher in hereditary cases than in sporadic ones. Full study results: nej.md/44aWRDP

Our kidney cancer research team @DanaFarber_GU meeting for the 1st time #legend @motzermd at #ASCO25 after the oral session ! @ASCO @MSKCancerCenter

Great to record @theviewongu with @lalaniMD at #aua25 Stay tuned for the episode coming out soon!

🚨OUT NOW: Episode 21 - featuring #ProstateCancer imaging expert, Dr. Frédéric Pouliot from @crchuqc! In today’s episode, Dr. Pouillot, Dr. @LalaniMD and Dr. @WallisCJD dive into the evolving role of PSMA PET and so much more: theviewongu.ca

Not all #ProstateCancer is equal, and in Episode 20, Dr. Katherine Zukotynski of @McMasterU, Dr. @LalaniMD, and Dr. @WallisCJD break down how the total burden of disease affects treatment decisions, and why it matters for every patient. Learn more: theviewongu.ca.

Theranostics is changing the game in #ProstateCancer care. In Ep. 20 of The View on GU, Dr. Katherine Zukotynski (@McMasterU) joins Dr. @lalaniMD and Dr. @WallisCJD to unpack how PSMA-targeted tracers are transforming the way we look at prostate cancer: theviewongu.ca

Episode 20 of The View on GU is officially live! 🥳🎉 Special guest Dr. Katherine Zukotynski joins Dr. @LalaniMD and Dr. @WallisCJD to discuss radioligand therapy. Watch or listen to Episode 20 now! theviewongu.ca.

Join us for this event in #RCC.Navigating the Evolving Landscape of Renal Cell Carcinoma: From Case Studies to Comprehensive Care. Sign up for free: cuaregistration.org/navigating-the… #kidney #section1credits @lalaniMD @Ramysaleh86

Filmed live at @ASCO GU, in Episode 17 of The View on GU, Dr @LalaniMD & Dr @WallisCJD consider “the age-old question” when it comes to prostate cancer: radiation or surgery? To listen, visit theviewongu.ca. Part 2 & Part 3 of this @ASCO mini-series is coming soon! #GU25

🚨Episode 18 is out! The second episode in our mini-series from @ASCO GU focuses on #BladderCancer. Dr. @lalaniMD & Dr. @WallisCJD talk about CheckMate 247, a Phase 3 clinical trial using adjuvant nivolumab in resected urothelial cancer. Check it out at theviewongu.ca!

#GU25: Longer term follow up for front-line #RCC combinations — many studies now with ~5+ years! 🚨 👏 Bar is set for next disruptors (MOAs?) to displace @DrChoueiri @tompowles1 @brian_rini @motzermd @AlbigesL @DrRanaMcKay @montypal @neerajaiims @DrYukselUrun @OncoAlert @ASCO

We'll be filming live at 2025 @ASCO Genitourinary Cancer Symposium, which starts tomorrow! @lalaniMD and @WallisCJD will weigh-in with their reactions, considerations, and key learnings from the sessions and presentations in an exciting 3-episode series. Stay tuned! #GU25

Ab#96 @ASCO #GU25 by @WallisCJD👉bit.ly/3EqF5TB👉In pts w/ de novo mHSPC #prostatecancer (n = 6051) 👉Only 24% received intensified ADT & sociodemographic marginalization was associated w/ ⬇️rates of intensified Rx👇@lalaniMD @OncoAlert @urotoday @PCF_Science

1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin…